IPP Bureau
Camurus’ Oclaiz NDA resubmission accepted by FDA
By IPP Bureau - January 14, 2026
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Pierre Fabre and Iktos team up to accelerate AI-driven cancer drug discovery
By IPP Bureau - January 14, 2026
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy
By IPP Bureau - January 14, 2026
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents
By IPP Bureau - January 14, 2026
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
FDA nod to first-ever treatment for fatal pediatric Menkes disease
By IPP Bureau - January 14, 2026
Bengaluru’s STEERLife and Bionpharma secure USFDA nod for generic HIV drug
By IPP Bureau - January 14, 2026
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
US healthcare costs spark push for Ayurveda integration
By IPP Bureau - January 14, 2026
Thermo Fisher and NVIDIA team up to supercharge labs with AI
By IPP Bureau - January 14, 2026
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
BioMed X launches Harvard pilot to connect academia and pharma
By IPP Bureau - January 14, 2026
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery
By IPP Bureau - January 14, 2026
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
GEA to power new biotechnology fermentation hub in Netherlands
By IPP Bureau - January 14, 2026
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
Metropolis Healthcare launches Genomics Centre to scale precision diagnostics and research
By IPP Bureau - January 14, 2026
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
Firstsource acquires TeleMedik
By IPP Bureau - January 14, 2026
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
Dr. Reddy’s launches first generic equivalent of extra-strength Pataday in US
By IPP Bureau - January 14, 2026
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
NVIDIA & Eli Lilly launch $1 billion AI Lab to reinvent drug discovery
By IPP Bureau - January 13, 2026
